BioSpace News Archive

Applied Genetic Technologies Corporation today announced the appointment of Susan Schneider, M.D., as Chief Medical Officer (CMO) and Sarah C. DiSalvatore, M.P.H., as Vice President of Clinical Operations.

Globus Medical , Inc. will announce its financial results for the third quarter ended September 30, 2021 after the market close on Thursday, November 4, 2021.

XORTX Therapeutics Inc. is pleased to announce and share the results of an American Society of Nephrology Kidney Week abstract by Dr. Steven Coca and team at Mount Sinai Hospital Network and Icahn School of Medicine, that will be published online Friday, October 15, 2021

The Board of Directors of Sensient Technologies Corporation (NYSE: SXT) has declared a regular quarterly cash dividend on its common stock of $0.41 per share, an increase of 5.1% per share.

Inotiv intends to use the net proceeds from the offering of notes, together with borrowings under a new senior secured term loan facility, to fund the cash purchase price of Inotiv’s previously announced acquisition of Envigo RMS Holding Corp. (the “Envigo acquisition”), if it is consummated, and to pay related fees and expenses.

Life Sciences British Columbia (LSBC) announces the 31 companies presenting to the 6th annual Invest in BC presented by Lumira Ventures on November 3 and 4, 2021

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today its first-in-class once-daily oral capsule AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), which was approved by the U.S. Food and Drug Administration (FDA) in March 2021.

OpGen, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 150,000 shares of convertible preferred stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday, October 28, 2021, before the U.S. financial markets open.